Sugi Predict

Sugi Predict / Compounds / SCHEMBL837092

SCHEMBL837092

SCHEMBL837092

CCOC(OCC)C(=O)c1ccc(Br)c(F)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC6A4 P31645 3/20 0.40
▸ CES2 O00748 2/20 0.37
▸ CES1 P23141 2/20 0.37
▸ CHRNA1 P02708 2/20 0.37
▸ CHRNG P07510 2/20 0.37
▸ CHRNB1 P11230 2/20 0.37
▸ CHRNB2 P17787 2/20 0.37
▸ SLC6A2 P23975 2/20 0.37
▸ CHRNB4 P30926 2/20 0.37
▸ CHRNA3 P32297 2/20 0.37
▸ CHRNA4 P43681 2/20 0.37
▸ SLC6A3 Q01959 2/20 0.37
▸ CHRND Q07001 2/20 0.37
▸ TAS1R3 Q7RTX0 1/20 0.35
▸ TAS1R1 Q7RTX1 1/20 0.35
▸ LMNA P02545 2/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ HDAC1 Q13547 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29420348 1.00 SLC6A4 (0.40) SLC6A4CES2CES1CHRNA1CHRNG
SCHEMBL13623614 0.83 HDAC1 (0.50) CES2CES1CHRNA1CHRNGCHRNB1
SCHEMBL22230657 0.82 L3MBTL1 (0.38) SLC6A4CES2CES1CHRNA1CHRNG
SCHEMBL17275631 0.78 GAA (0.52) SLC6A4CES2CES1CHRNA1CHRNG
SCHEMBL838263 0.78 KDM4E (0.43) CHRNA1CHRNGCHRNB1CHRNB2SLC6A2
SCHEMBL664187 0.78 CA12 (0.56) LMNAMAPK1HTTRAB9AHDAC1
SCHEMBL11362698 0.77 CA12 (0.42) LMNAHTTRAB9ASMN1; SMN2ALDH1A1
SCHEMBL837583 0.76 SLC6A2 (0.46) CES2CES1SLC6A2SLC6A3LMNA
SCHEMBL15309561 0.76 SLC6A2 (0.46) SLC6A4CES2CES1SLC6A2SLC6A3
SCHEMBL837691 0.76 CES2 (0.47) SLC6A4CES2CES1CHRNA1CHRNG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12427154-B2 Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same INCYTE HOLDINGS CORPORATION (US) 2025-09-30 — — US disclosed
US-20250223291-A1 IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS INCYTE CORPORATION 2025-07-10 — — US disclosed
US-12084449-B2 Imidazotriazines and imidazopyrimidines as kinase inhibitors INCYTE HOLDINGS CORPORATION (US) 2024-09-10 — — US disclosed
US-20230098850-A1 SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)- IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME INCYTE CORPORATION 2023-03-30 — — US disclosed
US-20230002392-A1 Imidazotriazines and Imidazopyrimidines as Kinase Inhibitors INCYTE CORPORATION 2023-01-05 — — US disclosed
US-11452726-B2 Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same INCYTE CORPORATION (US) 2022-09-27 — — US disclosed
US-11261191-B2 Imidazotriaines and imidazopyrimidines as kinase inhibitors INCYTE HOLDINGS CORPORATION (US) 2022-03-01 — — US disclosed
US-20210128568-A1 SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)- IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME INCYTE CORPORATION 2021-05-06 — — US disclosed
US-10919901-B2 Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors INCYTE HOLDINGS CORPORATION (US) 2021-02-16 — — US disclosed
US-10919901-B2 Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors INCYTE HOLDINGS CORPORATION (US) 2021-02-16 — — US disclosed
WO-2009143211-A2 SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)- IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME INCYTE CORPORATION (US) 2009-11-26 — — WO disclosed
US-20090291956-A1 SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)-IMIDAZO[1,2-b][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME INCYTE CORPORATION 2009-11-26 — — US disclosed
US-20090291956-A1 SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)-IMIDAZO[1,2-b][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME INCYTE CORPORATION 2009-11-26 — — US disclosed
US-20090291956-A1 SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)-IMIDAZO[1,2-b][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME INCYTE CORPORATION 2009-11-26 — — US disclosed
EP-2099447-A1 IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS Incyte Corporation (US) 2009-09-16 — — EP disclosed
EP-2057164-A1 TRIAZOLOTRIAZINES AS KINASE INHIBITORS Incyte Corporation (US) 2009-05-13 — — EP disclosed
US-20080167287-A1 IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS INCYTE CORPORATION (US) 2008-07-10 — — US disclosed
WO-2008064157-A1 IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS INCYTE CORPORATION (US) 2008-05-29 — — WO disclosed
WO-2008021781-A1 TRIAZOLOTRIAZINES AS KINASE INHIBITORS INCYTE CORPORATION (US) 2008-02-21 — — WO disclosed
US-20080039457-A1 TRIAZOLOTRIAZINES AS KINASE INHIBITORS INCYTE CORPORATION (US) 2008-02-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11452726-B2 Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same ABL1, MET, ABL2 SLC6A4 2150/4885CES2 2433/4885CES1 2422/4885
US-20080039457-A1 TRIAZOLOTRIAZINES AS KINASE INHIBITORS MET, ERBB2, RET SLC6A4 2854/4885CES2 2294/4885CES1 2484/4885
US-12427154-B2 Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same ABL1, MET, ABL2 SLC6A4 2150/4885CES2 2433/4885CES1 2422/4885
US-20230098850-A1 SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)- IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME ABL1, MET, ABL2 SLC6A4 2150/4885CES2 2433/4885CES1 2422/4885
US-20230002392-A1 Imidazotriazines and Imidazopyrimidines as Kinase Inhibitors ERBB2, MERTK, ABL1 SLC6A4 3368/4885CES2 2681/4885CES1 2562/4885
US-20250223291-A1 IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS ERBB2, MERTK, ABL1 SLC6A4 3368/4885CES2 2681/4885CES1 2562/4885
US-20210128568-A1 SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)- IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME ABL1, MET, ABL2 SLC6A4 2150/4885CES2 2433/4885CES1 2422/4885
US-10919901-B2 Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors MET, RET, ERBB2 SLC6A4 2644/4885CES2 1863/4885CES1 1096/4885
US-12084449-B2 Imidazotriazines and imidazopyrimidines as kinase inhibitors ERBB2, MERTK, ABL1 SLC6A4 3368/4885CES2 2681/4885CES1 2562/4885
US-20090291956-A1 SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)-IMIDAZO[1,2-b][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAME ABL1, MET, ABL2 SLC6A4 2150/4885CES2 2433/4885CES1 2422/4885
US-11261191-B2 Imidazotriaines and imidazopyrimidines as kinase inhibitors MET, RET, ERBB2 SLC6A4 3384/4885CES2 2767/4885CES1 2426/4885
US-20080167287-A1 IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS ERBB2, MERTK, ABL1 SLC6A4 3368/4885CES2 2681/4885CES1 2562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.